A portion of this work was supported by an unrestricted research grant by AbbVie Inc. Huntsman Cancer Institute provided partial support for all datasets within the Utah Population Database. The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Drs. Kuo, Stenehjem, Albright, and Brixner are partially paid through the University of Utah via an unrestricted research grant from AbbVie Inc. Dr. Ray is employed by or holds a leadership position with AbbVie Inc.
A portion of this study was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 5th Asia-Pacific Conference; September 2–4, 2012; Taipei, Taiwan.
The authors would like to acknowledge Reed Barney and Brian Oberg for data extraction and management from the University of Utah Enterprise Data Warehouse.
Cancer Facts & Figures 2013. American Cancer Society Web site. Available at: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013. Accessed July 20, 2015.
Tanaka Y, Hanada K, Mizokami M et al.. Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002;99:15584–15589.
- Search Google Scholar
- Export Citation
. Tanaka Y Hanada K Mizokami M Inaugural article: a comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002; 99: 15584– 15589.
Velazquez RF, Rodriguez M, Navascues CA et al.. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2033;37:520–527.
American Cancer Society. What is liver cancer? Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.pdf. Accessed July 29, 2015.
Wildi S, Pestalozzi BC, McCormack L et al.. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400–408.
Cillo U, Vitale A, Grigoletto F et al.. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–731.
Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928.
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338.
Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 2010;15(Suppl 4):23–33.
Benson AB III, D'Angelica MI, Abrams TA et al.. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2, 2015. Available at: NCCN.org. Accessed July 20, 2015.
Charlson ME, Pompei P, Ales KL et al.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
Farinati F, Sergio A, Baldan A et al.. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009;9:33.
Wang JH, Changchien CS, Hu TH et al.. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: survival analysis of 3892 patients. Eur J Cancer 2008;44:1000–1006.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–442.
Takayasu K, Arii S, Ikai I et al.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461–469.
Kim J, Ko ME, Nelson RA et al.. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg 2014;218:431–438.
Hanazaki K, Kajikawa S, Shimozawa N et al.. Hepatic resection for hepatocellular carcinoma in the elderly. J Am Coll Surg 2001;192:38–46.
Yang D, Hanna DL, Usher J et al.. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer 2014;120:3707–3716.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–755.
Leung TW, Tang AM, Zee B et al.. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760–1769.
- Search Google Scholar
- Export Citation
. Leung TW Tang AM Zee B Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760– 1769.
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207–215.
Chevret S, Trinchet JC, Mathieu D et al.. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:133–141.
Dohmen K. Many staging systems for hepatocellular carcinoma: evolution from Child-Pugh, Okuda to SLiDe. J Gastroenterol Hepatol 2004;19:1227–1232.
Saraswat VA, Pandey G, Shetty S. Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S80–89.